Ian Bridges

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Low Density Lipoprotein

Ejection Fraction

End Stage Renal Disease

Clinical Practice

Top Venues

Advances in therapy

Wiener klinische Wochenschrift

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy (2024)
Michael Lehrke, Anja Vogt, Volker J J Schettler, Matthias Girndt, Uwe Fraass, Anja Tabbert-Zitzler, Ian Bridges, Nafeesa N Dhalwani, Kausik K Ray
Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study. Advances in therapy 41 (3) (2024)
Christoph Ebenbichler, Heinz Drexel, Ursula Hanusch, Hermann Toplak, Nafeesa N Dhalwani, Ian Bridges, Robert Hoelzl, Margit Hemetsberger, Kausik K Ray
Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study. Wiener klinische Wochenschrift (2023)